Neonatal Vitamin D Status Linked to Schizophrenia Risk
By LabMedica International staff writers Posted on 18 Dec 2018 |

Image: The Nexera X2 Ultra High Performance Liquid Chromatography (UHPLC) system (Photo courtesy of Shimadzu).
Schizophrenia is a poorly understood group of brain disorders characterized by impairments in cognition, perception and affect, with a lifetime prevalence of 0.7%. People with schizophrenia may seem like they have lost touch with reality.
As with other heterogeneous disorders, the expectation is that schizophrenia is associated with many different causal factors involving both common and rare genetic variants, as well as a range of environmental exposures. With respect to environmental risk factors for schizophrenia, much attention has focused on modifiable prenatal and early life exposures.
A team of scientists from Australia and Denmark working with the University of Queensland (St. Lucia, Australia) analyzed vitamin D (25OHD) concentration in dried blood samples taken from Danish newborns between 1981 and 2000 who went on to develop schizophrenia as young adults. Most of these cases developed schizophrenia between September 2005 and December 2008. Controls, drawn from the same birth cohort, were individually matched on sex and date of birth, and were alive and free of schizophrenia at the time of onset of the matched case. The dried blood spots (DBS) were stored at -20 ⁰C.
DBS (samples and calibrants) were hydrated and processed and analyzed on a liquid chromatography–tandem mass spectrometry (LC-MS/MS) system consisted of a Nexera X2 UHPLC, comprising a SIL-30AC autosampler (50 µL loop), two LC-30AD binary pumps, DGU-20A5 degasser, and CTO-30A oven, and interfaced to a 5500 QTRAP mass spectrometer with Atmospheric Pressure Chemical Ionisation (APCI) TurboIonSpray ion source. DNA was extracted from the neonatal dried blood spots and genotyped.
The scientists reported that based on the combined sample, both the lowest and second lowest 25OHD quintiles were associated with an increased risk of schizophrenia compared to the reference fourth quintile. None of the other comparisons were statistically significant. This confirmed that neonatal vitamin D deficiency was associated with a significantly increased risk of schizophrenia. Those with 25OHD below 20.4 nmol/L, which is consistent with standard definitions of vitamin D deficiency, had a 44% increased risk of schizophrenia compared to those in the reference category.
John McGrath, MD, PhD, a professor of psychiatry and lead author of the study said, “We hypothesized that low vitamin D levels in pregnant women due to a lack of sun exposure during winter months might underlie this risk, and investigated the association between vitamin D deficiency and risk of schizophrenia. As the developing fetus is totally reliant on the mother's vitamin D stores, our findings suggest that ensuring pregnant women have adequate levels of vitamin D may result in the prevention of some schizophrenia cases, in a manner comparable to the role folate supplementation has played in the prevention of spina bifida.” The study was published on December 6, 2018, in the journal Scientific Reports.
Related Links:
University of Queensland
As with other heterogeneous disorders, the expectation is that schizophrenia is associated with many different causal factors involving both common and rare genetic variants, as well as a range of environmental exposures. With respect to environmental risk factors for schizophrenia, much attention has focused on modifiable prenatal and early life exposures.
A team of scientists from Australia and Denmark working with the University of Queensland (St. Lucia, Australia) analyzed vitamin D (25OHD) concentration in dried blood samples taken from Danish newborns between 1981 and 2000 who went on to develop schizophrenia as young adults. Most of these cases developed schizophrenia between September 2005 and December 2008. Controls, drawn from the same birth cohort, were individually matched on sex and date of birth, and were alive and free of schizophrenia at the time of onset of the matched case. The dried blood spots (DBS) were stored at -20 ⁰C.
DBS (samples and calibrants) were hydrated and processed and analyzed on a liquid chromatography–tandem mass spectrometry (LC-MS/MS) system consisted of a Nexera X2 UHPLC, comprising a SIL-30AC autosampler (50 µL loop), two LC-30AD binary pumps, DGU-20A5 degasser, and CTO-30A oven, and interfaced to a 5500 QTRAP mass spectrometer with Atmospheric Pressure Chemical Ionisation (APCI) TurboIonSpray ion source. DNA was extracted from the neonatal dried blood spots and genotyped.
The scientists reported that based on the combined sample, both the lowest and second lowest 25OHD quintiles were associated with an increased risk of schizophrenia compared to the reference fourth quintile. None of the other comparisons were statistically significant. This confirmed that neonatal vitamin D deficiency was associated with a significantly increased risk of schizophrenia. Those with 25OHD below 20.4 nmol/L, which is consistent with standard definitions of vitamin D deficiency, had a 44% increased risk of schizophrenia compared to those in the reference category.
John McGrath, MD, PhD, a professor of psychiatry and lead author of the study said, “We hypothesized that low vitamin D levels in pregnant women due to a lack of sun exposure during winter months might underlie this risk, and investigated the association between vitamin D deficiency and risk of schizophrenia. As the developing fetus is totally reliant on the mother's vitamin D stores, our findings suggest that ensuring pregnant women have adequate levels of vitamin D may result in the prevention of some schizophrenia cases, in a manner comparable to the role folate supplementation has played in the prevention of spina bifida.” The study was published on December 6, 2018, in the journal Scientific Reports.
Related Links:
University of Queensland
Latest Clinical Chem. News
- AI-Powered Blood Test Accurately Detects Ovarian Cancer
- Automated Decentralized cfDNA NGS Assay Identifies Alterations in Advanced Solid Tumors
- Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication
- First Comprehensive Syphilis Test to Definitively Diagnose Active Infection In 10 Minutes
- Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse
- ‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
- Low-Cost Portable Screening Test to Transform Kidney Disease Detection
- New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
- Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
- Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
- AI-Powered Raman Spectroscopy Method Enables Rapid Drug Detection in Blood
- Novel LC-MS/MS Assay Detects Low Creatinine in Sweat and Saliva
- Biosensing Technology Breakthrough Paves Way for New Methods of Early Disease Detection
- New Saliva Test Rapidly Identifies Paracetamol Overdose
- POC Saliva Testing Device Predicts Heart Failure in 15 Minutes
- Screening Tool Detects Multiple Health Conditions from Single Blood Drop
Channels
Molecular Diagnostics
view channel
POC Oral Swab Test to Increase Chances of Pregnancy in IVF
Approximately 15% of couples of reproductive age experience involuntary childlessness. A significant reason for this is the growing trend of delaying family planning, a global shift that is expected to... Read more
Microbial Cell-Free DNA Test Accurately Identifies Pathogens Causing Pneumonia and Other Lung Infections
Bronchoalveolar lavage (BAL) is a commonly used procedure for diagnosing lung infections, especially in immunocompromised patients. However, standard tests often fail to pinpoint the exact pathogen, leading... Read moreHematology
view channel
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read more
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
New Blood Test Detects Up to Five Infectious Diseases at POC
Researchers have developed a prototype flow-through assay capable of detecting up to five different infections, with results that can be quickly analyzed and transmitted via a specialized smartphone app.... Read more
Molecular Stool Test Shows Potential for Diagnosing TB in Adults with HIV
Tuberculosis (TB), caused by the bacterium Mycobacterium tuberculosis, led to 1.25 million deaths in 2023, with 13% of those occurring in people living with HIV. The current primary diagnostic method for... Read morePathology
view channel
Groundbreaking Chest Pain Triage Algorithm to Transform Cardiac Care
Cardiovascular disease is responsible for a third of all deaths worldwide, and chest pain is the second most common reason for emergency department (ED) visits. With EDs often being some of the busiest... Read more
AI-Based Liquid Biopsy Approach to Revolutionize Brain Cancer Detection
Detecting brain cancers remains extremely challenging, with many patients only receiving a diagnosis at later stages after symptoms like headaches, seizures, or cognitive issues appear. Late-stage diagnoses... Read moreTechnology
view channel
Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer
Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read moreIndustry
view channel
Qiagen Acquires NGS Analysis Software Company Genoox
QIAGEN (Venlo, the Netherlands) has signed a definitive agreement to acquire Genoox (Tel Aviv, Israel), a provider of artificial intelligence (AI)-powered software that enables clinical labs to scale and... Read more
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more